Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03737812 (ClinicalTrials.gov)	February 27, 2019	6/11/2018	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie	NULL	Completed	18 Years	65 Years	All	123	Phase 2	United States;Canada
2	NCT03737851 (ClinicalTrials.gov)	December 11, 2018	6/11/2018	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie	NULL	Completed	18 Years	65 Years	All	208	Phase 2	United States;Canada